Manila, Philippines – The Food and Drug Administration (FDA) has ordered a recall of eight drug products for having no certificate of product registration.
“Based on the results of the recent investigations conducted by the Food and Drug Administration, it was found that there are products marketed by Eli Lilly (Philippines) Inc. without valid Certificate of Product Registration (CPR), hence unregistered,” according to the advisory signed by FDA acting Director General Kenneth Hartigan-Go.
The drug products ordered recalled by the FDA were Prozac (generic name Fluoxetine) 20 mg capsule, Strattera (Atomoxetine) in 10 mg, 18 mg, 25 mg, 40 mg, and 60 mg capsules, Zyprexa Zydis (Olanzapine) 10 mg orodispersible tablet, and Zyprexa IM (Olanzapine) 10 mg powder for injection.
“The physicians are hereby warned against prescribing these products. Also, the public is advised to refrain from buying and using these products,” the advisory said.
FDA inspectors have been ordered to ensure that the products will not be found in the warehouses of Eli Lilly distributors and in retail drugstores after Eli Lilly has finished the recall.
Recently, the FDA ordered the recall of Tadalafil (Cialis) 20 mg tablet, a drug for erectile dysfunction marketed by Eli Lilly Philippines, for having no certificate of product registration. (Jonathan Hicap)
Incoming search terms:
- eli lilly philippines news (3)
- eli lilly fda 2014 philippines (2)
- eli lilly philippines fda (2)
- lilly philippines recall (1)
- lilly philippines (1)